Want to see IL:NURI full AI Analyst Report?
Top Page
Nur
(TASE:NURI)
Select Model
Select Model
Rating:44Neutral
Price Target:
719.00
▼(-12.13% Downside)
Action:Reiterated
Date:08/26/26
The score is driven primarily by weak financial performance—large ongoing losses and significant cash burn outweigh the healthier leverage position. Technicals are also a headwind given the strong downtrend, with only an oversold RSI offering limited near-term support. Valuation signals are constrained because the company is loss-making and offers no dividend yield.
Positive Factors
Revenue Rebound
The revenue rebound indicates improving commercial activity and product adoption. Although the base remains very small, sustained growth could strengthen operating leverage and provide a foundation for future scale.
Negative Factors
Deep Unprofitability
Negative gross profit means the core business is not currently covering direct costs, while the large net loss shows substantial overhead burden. Persistent unprofitability weakens resilience and delays internally funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Rebound
The revenue rebound indicates improving commercial activity and product adoption. Although the base remains very small, sustained growth could strengthen operating leverage and provide a foundation for future scale.
Read all positive factors
Nur (NURI) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪62.26M
Dividend YieldN/A
Average Volume (3M)8.76K
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue Growth104.30%
EPS Growth2.80%
CountryIL
Employees18
SectorGeneral
Sector StrengthN/A
IndustryIndustrial - Specialties
Share Statistics
EPS (TTM)N/A
Shares Outstanding8,763,420
10 Day Avg. Volume16,677
30 Day Avg. Volume8,763
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)5.13
Price to Sales (P/S)265.22
P/FCF Ratio-11.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nur Business Overview & Revenue Model
Company Description
Nur Ink Innovations Ltd engages in the design, development, and production of water-based pigmented inks for digital inkjet printing applications in Israel. It offers Digital Sol-Gel, a water-based pigment ink for digital printing for direct-to-ga...
Nur Financial Statement Overview
Summary
Income Statement
9
Very Negative
Balance Sheet
54
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 380.00K | 327.00K | 253.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -3.33M | -3.06M | -2.69M | -1.72M | -84.00 | -137.00 |
| EBITDA | -8.37M | -6.99M | -7.56M | -11.35K | -10.18M | -7.07M |
| Net Income | -11.24M | -9.42M | -9.66M | -12.86M | -11.61M | -7.78M |
Balance Sheet | ||||||
| Total Assets | 20.65M | 22.74M | 18.39M | 21.83K | 33.29K | 41.07K |
| Cash, Cash Equivalents and Short-Term Investments | 699.00K | 4.14M | 5.63M | 10.44K | 21.33K | 32.90K |
| Total Debt | 1.89M | 2.17M | 2.70M | 2.70K | 3.12K | 3.51K |
| Total Liabilities | 6.05M | 5.84M | 5.56M | 5.76K | 5.48K | 5.28K |
| Stockholders Equity | 14.60M | 16.90M | 12.83M | 16.08K | 27.80K | 35.80K |
Cash Flow | ||||||
| Free Cash Flow | -8.99M | -7.85M | -7.13M | -10.17K | -8.09K | -9.12K |
| Operating Cash Flow | -8.56M | -7.50M | -6.61M | -9.32K | -6.27K | -6.34K |
| Investing Cash Flow | -4.86M | -155.00K | 418.00K | 485.00 | -14.40K | -3.31K |
| Financing Cash Flow | 13.12M | 10.04M | 5.22M | -447.00 | -385.00 | 42.39K |
Nur Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | ₪20.40B | 40.60 | ― | 0.65% | 62.12% | 46.67% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | ₪62.26M | -4.90 | ― | ― | 104.30% | 2.80% | |
44 Neutral | ₪40.80M | -0.50 | ― | ― | -40.18% | 67.38% | |
42 Neutral | ₪40.65M | -2.60 | ― | ― | -38.60% | -428.31% | |
41 Neutral | ₪40.36M | -4.12 | ― | ― | 12.14% | 43.83% |
* General Sector Average
IL:NURI
Nur
705.00
-181.10
-20.44%
IL:VISN
Vision Sigma
3,843.00
-1,254.00
-24.60%
IL:SCDX
Scodix
120.60
-142.01
-54.08%
IL:PHTM
Photomyne
1,480.00
-868.00
-36.97%
IL:MSVT
Massivit
55.80
-44.60
-44.42%
IL:NXSN
Next Vision
22,280.00
7,610.00
51.87%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.